Share this article
Share this article
JERSEY CITY, N.J., Jan. 14, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced upgrades to its out-of-pocket assistance program that aim to provide enhanced support for eligible patients with amyotrophic lateral sclerosis (ALS) treated with RADICAVA
® (edaravone) through more efficient communication and exchange of information, including a new "hybrid" card that can be used to help access appropriate pharmacy and medical co-pay assistance.
"Our modified 'all-in-one' out-of-pocket assistance program was designed with our patients in mind, to continue to support appropriate, affordable access to treatment with RADICAVA, for eligible patients," said Kevin O'Brien, Vice President of Market Access, MTPA. "We changed the program processes for handling pharmacy and medical benefit claims to allow patients to use one card, on-the-spot. In addition, we have modified logistical procedures related to co-pay issues for healthcare providers."